Information  X 
Enter a valid email address

Frutarom Industries (FRUT)

  Print      Mail a friend

Thursday 31 May, 2018

Frutarom Industries

Completion of the Bremil Acquisition

RNS Number : 7968P
Frutarom Industries Limited
31 May 2018
 

Below is the immediate report submitted today to the Israeli Securities Authority ("ISA") and the Tel-Aviv Stock Exchange through the ISA's electronic submission system in accordance with the Securities Regulations (Periodic and Immediate Reports), 1970.

 

 

Frutarom Industries Ltd.

("Company" or "Frutarom")

Registration No.:  52-004280-5

The securities of the Company are listed for trading on the Tel-Aviv Stock Exchange

Name:  Frutarom

2 Hamenofim St, Building A, Herzelia 4672553

Tel:  +972-9-960 3800, Fax:  +972-9-960 3826, www.frutarom.com

Email: [email protected]

 

 

May 31, 2018

 

Israeli Securities Authority

Tel Aviv Stock Exchange Ltd.

http://www.isa.gov.il/

http://www.tase.co.il/

 

Dear Sir/Madam,

Subject: Completion of the Bremil Acquisition

 

Following Frutarom's immediate report from December 20, 2017, regarding the purchase of 51% of the shares of the Brazilian company Bremil Indústria De Produtos Alimentícios Ltda. ("Bremil"), Frutarom is proud to announce that on May 30, 2018, the above transaction was completed, as the Company purchased 51% of Bremil's shares for approx. US$ 30 million (BRL 111 million), including estimated adjustments for assets at the date of completion. The transaction was financed through bank debt.

 

For further information on the Bremil acquisition, see abovementioned immediate report.

 

Frutarom does not view this transaction as the purchase of a material asset.

 

 

Sincerely yours,

Eden Senay Tagania, Legal Counsel

Frutarom Industries Ltd.

 

 


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.
 
END
 
 
ACQEFLBXVEFZBBD

a d v e r t i s e m e n t